The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cisplatin plus irinotecan versus cisplatin plus gemcitabine in the treatment of advanced or metastatic gallbladder or biliary tract cancer: Results of a randomized phase II trial (NCT01859728)– the Gambit trial.
 
Lucas Vieira dos Santos
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD
Speakers' Bureau - BMS Brazil; BMS Brazil; BMS Brazil; BMS Brazil; United Medical; United Medical; United Medical; United Medical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); BMS Brazil (Inst); BMS Brazil (Inst); BMS Brazil (Inst); BMS Brazil (Inst); Boston Scientific (Inst); Boston Scientific (Inst); Boston Scientific (Inst); Boston Scientific (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Gustavo Sanches Faria Pinto
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis
 
Mauricio Wagner Souto Ferraz
No Relationships to Disclose
 
Arinilda Bragagnoli
No Relationships to Disclose
 
Florinda Santos
No Relationships to Disclose
 
Sarah Haddad
No Relationships to Disclose
 
Ana Barros
No Relationships to Disclose
 
Isadora Clarissa Cordeiro Dias
No Relationships to Disclose
 
Joao Paulo SN Lima
Stock and Other Ownership Interests - Amgen; Amgen; Amgen; Amgen; Bluebird Bio; Bluebird Bio; Bluebird Bio; Bluebird Bio; Myriad Genetics; Myriad Genetics; Myriad Genetics; Myriad Genetics; United Health Group; United Health Group; United Health Group; United Health Group
Honoraria - BMS Brazil; BMS Brazil; BMS Brazil; BMS Brazil; Libbs; Libbs; Libbs; Libbs; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis
Consulting or Advisory Role - Roche; Roche; Roche; Roche
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BMS Brazil (Inst); BMS Brazil (Inst); BMS Brazil (Inst); BMS Brazil (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Libbs (Inst); Libbs (Inst); Libbs (Inst); Libbs (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis
 
Kathia C Abdalla
No Relationships to Disclose